Beyond Numbers: How Liver Disease Scores Predict Inflammation
"Uncover how Child-Turcotte-Pugh (CTP) and MELD scores go beyond liver disease severity to reveal systemic inflammation in transplant patients."
In the world of liver disease, doctors rely on tools like the Child-Turcotte-Pugh (CTP) classification and the Model for End-Stage Liver Disease (MELD) score. These systems are designed to assess the severity of liver damage, helping to guide treatment decisions and predict patient outcomes. But what if these scores could tell us even more?
New research suggests that the CTP classification and MELD score might also serve as indicators of systemic inflammation, a body-wide response that can significantly impact the health of liver transplant patients. Understanding this connection could lead to more personalized and effective treatment strategies.
This article delves into the findings of a recent study that explored the relationship between liver disease scores and inflammatory responses in individuals undergoing living-donor liver transplantation, shedding light on the potential for these tools to provide a more comprehensive picture of a patient's condition.
From Ancient Observation to Modern Hepatology
The history of hepatitis-virus discovery spans the last 50 years and includes cognitive milestones that revolutionized medicine and public health. The history of hepatology also reaches back to the second and first millennia B.C., when Babylonians and Assyrians placed importance on inspecting the liver. Modern understanding later expanded beyond visible symptoms such as jaundice, vomiting, abdominal swelling, and wasting to include bile acids, inflammatory cascades, microbiota, fibrosis, and portal circulation. NAFLD has since become the most common cause of chronic liver disease worldwide.
Decoding CTP and MELD: More Than Just Liver Scores?
Traditionally, the CTP classification and MELD score have been used to evaluate the extent of liver dysfunction. The CTP system assesses factors like bilirubin levels, albumin, ascites, and encephalopathy, while the MELD score considers bilirubin, creatinine, and INR (international normalized ratio) values. These scores help doctors determine the urgency of transplantation, predict survival rates, and manage other liver-related complications.
- Pro-inflammatory Cytokines: Substances like interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α, which promote inflammation.
- Anti-inflammatory Cytokines: Substances like IL-10 and IL-4, which help regulate and dampen down the inflammatory response.
How CTP and MELD Frame Severity
The Child-Turcotte-Pugh (CTP) and MELD indicators are used to establish liver-transplant priority, estimate prognosis, predict survival and mortality after transplantation, and assess health-related quality of life. CTP incorporates bilirubin, albumin, prothrombin time, ascites, and the degree of hepatic encephalopathy. Its severity classes are class A for scores 5-6, class B for scores 7-9, and class C for scores 10-15. These measures describe clinical severity and do not, by themselves, establish a direct measure of inflammatory activity.
Limits of Inflammation Inference
Cirrhosis progresses from compensated disease to decompensated cirrhosis and acute-on-chronic liver failure, with distinct clinical manifestations across stages. APASL defines acute-on-chronic liver failure as acute hepatic decompensation with liver failure, including jaundice and prolonged international normalized ratio, plus at least one extrahepatic organ failure and increased 28-day mortality. However, one transplantation study cautioned that differences in cytokine concentrations between healthy subjects and patients with liver failure might not accurately reflect disease severity because samples were collected in the operating room after anesthesia induction. This limitation shows why score-based severity and inflammatory measurements should not be treated as interchangeable.
Comparing Emerging Therapeutic Evidence
A 2026 systematic review and network meta-analysis examined the comparative efficacy of herbal products for improving liver enzymes and inflammation in metabolic dysfunction-associated steatotic liver disease. Its stated background notes that MASLD and metabolic dysfunction-associated steatohepatitis affect adults worldwide and cause morbidity. Lifestyle modification remains first-line therapy, while herbal agents are being studied for possible hepatometabolic effects. The available source material does not provide comparative outcome figures or establish that any specific herbal product is superior.
The Bigger Picture: Implications for Patient Care
The study's findings suggest that both the CTP classification and the MELD score can serve as valuable tools for predicting the severity of the systemic inflammatory response in liver transplant candidates, particularly before surgery. While inflammation is a complex process influenced by many factors, these scores offer a readily available way to assess a patient's inflammatory status, potentially leading to earlier interventions and improved outcomes.
Inflammation as a Multilayered Signal
The liver is the major organ producing acute-phase proteins, which are closely associated with inflammatory reactions, and immune-cell dysregulation contributes to the pathogenesis of many liver diseases. Research on the liver inflammation ecosystem identified the ANXA1-FPR1 axis as an interaction between T cells and myeloid cells that may dampen inflammation. Plasma and hepatic ANXA1 levels were elevated in patients with acute-on-chronic liver failure and correlated with disease severity. Inflammasome activation is also implicated in liver-disease development and has been proposed as a potential therapeutic target.
Forecasting a Diverse Disease Burden
Liver diseases include diverse disorders marked by hepatocyte injury, inflammatory-cell infiltration, and hepatic stellate-cell activation, processes that impair function and disrupt liver architecture. A 2025 review reports that liver diseases are linked annually to approximately 2 million deaths and account for 4% of global mortality. Viruses, alcohol, metabolites, toxins, and other pathogenic agents can cause acute or chronic injury that may progress to end-stage liver disease, while different liver diseases retain distinct pathophysiological, clinical, and therapeutic profiles. Chronic liver disease may evolve from inflammation to fibrosis and ultimately cirrhosis, a stage characterized by irreversible scarring and compromised function.